BioSpace News Archive

Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced the pricing of its previously announced underwritten public offering.

S2 Genomics, Inc., today announced that it has entered into a distribution agreement with D-Mark Biosciences for the promotion, sales, and support of S2’s Singulator™ 100 System and associated products for single-cell genomics and cell biology applications in Canada.

Emunamedica LLC, a wound diagnostics company announced today that Podascan™, its chronic wound diagnostic device had received Breakthrough Device Designation from the United States Food & Drug Administration (FDA).

These specialties also rank among the best programs in the U.S, providing Florida patients with a clear choice and resource to receive world-class care

Dr. Reddy’s Laboratories Ltd. announced its consolidated financial results for the quarter and the half year ended September 30, 2020.

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced that the Company’s Board of Directors has approved a fourth-quarter 2020 dividend of $0.17 per share, a 6.25% increase over the $0.16 per share declared for each of the four preceding quarters.

Agena Bioscience®, a global provider of low-cost and high-throughput molecular testing solutions, announced that its MassARRAY® SARS-CoV-2 Panel for qualitative detection of the SARS-CoV-2 coronavirus has been granted Emergency Use Authorization from the U.S. Food and Drug Administration.

ChromaDex Corp. announced that it will hold a conference call on Wed., November 4, 2020 at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2020.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced the first patient has been dosed in the Phase 1/2 ASPEN-02 study evaluating the combination of ALX148, a next-generation CD47 blocker, with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome.

Axsome to host conference call and webcast on Thursday, November 5, 2020 at 8:00 AM Eastern Time